Floatz logo

.GAMMA.-CYCLODEXTRIN, 6A,6B,6C,6D,6E,7F,6G,6H-OCTAKIS-S-(2-CARBOXYETHYL)-6A,6B,6C,6D,6E,7F,6G,6H-OCTATHIO-

Morbidly Obese Patients

University Hospital, GhentSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

66 Active assets in the Morbidly Obese Patients cohort.

Asset / SponsorPhaseRating
LIDOCAINE
Instituto Mexicano del Seguro Social
Phase 4BBB
Chenodeoxycholic Acid
Hvidovre University Hospital
Phase 4BBB
Colesevelam
Hvidovre University Hospital
Phase 4BBB
RAMIFENTANYL
Hospital dos Lusíadas
Phase 4BBB
PROPOFOL
G.Gennimatas General Hospital
Phase 4BBB

View all 50 →

Same molecule, other indications

.GAMMA.-CYCLODEXTRIN, 6A,6B,6C,6D,6E,7F,6G,6H-OCTAKIS-S-(2-CARBOXYETHYL)-6A,6B,6C,6D,6E,7F,6G,6H-OCTATHIO- is also rated in:

neuromuscular junction diseaseDormant
A
Indicative ·
84 / 100
View asset →
cirrhosis of liverDormant
BB
Indicative ·
69 / 100
View asset →
Surgical ConditionsDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →